Condition (MeSH)
Gastric Antral Vascular Ectasia
ClinicalTrials.gov lists 13 trials for Gastric Antral Vascular Ectasia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Gastric Antral Vascular Ectasia itself; the rest are tagged with a narrower condition beneath it.
When did Gastric Antral Vascular Ectasia trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2015 | 1 |
| 2012 | 1 |
| 2007 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gastric Antral Vascular Ectasia trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 5 |
| Observational | 5 |
How many Gastric Antral Vascular Ectasia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Completed | 4 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Gastric Antral Vascular Ectasia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| THALIDOMIDE | 2 |
| Iron | 1 |
Interventions as named in the registry (1)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| CRYOTHERAPY | 2 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Gastric Antral Vascular Ectasia? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Comparative Effectiveness and Safety of Radiofrequency Ablation Versus Argon Plasma Coagulation for Treatment of Gastric Antral Vascular Ectasia: A Systematic Review and Meta-Analysis. | Journal of clinical gastroenterology | 2019 | Yes |
| Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia. | United European gastroenterology journal | 2019 | Yes |
| Gastric antral vascular ectasia: a prospective study of treatment with endoscopic band ligation. | Endoscopy | 2015 | Yes |
| Intravenous cyclophosphamide as a therapeutic option for severe refractory gastric antral vascular ectasia in systemic sclerosis. | Internal medicine journal | 2015 | Yes |
| Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2014 | Yes |
Showing 5 of 21 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.